Mizuho Adjusts Nurix Valuation Following Roche Partnership

Mizuho has officially raised its price target for Nurix Therapeutics to $34, a move catalyzed by the company's recent strategic partnership with Roche. This development serves as a significant signal for investors tracking the biotech sector, particularly…